Buy Vegzelma (Bevacizumab-adcd)
Price range: €375.00 through €1,125.00
Select options
This product has multiple variants. The options may be chosen on the product page
Vegzelma (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), the main driver of vasculogenesis and angiogenesis, and inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (VEGFR-2) on the surface of endothelial cells.
Vegzelma is indicated for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent or metastatic cervical cancer; and epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.